AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D ...

Perhaps that’s why, in a wood-paneled conference room at the St. Regis Hotel far from the hubbub of the American Society of Clinical Oncology’s annual meeting, Pascal Soriot, AstraZeneca’s ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a ...

AstraZeneca Chief Executive Pascal Soriot in a press briefing acknowledged that monitoring patients for drug resistance before cancer progresses would require a switch in practice, ...

CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca (NASDAQ:AZN)’s experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease ...

Meanwhile, AstraZeneca’s CEO, Pascal Soriot, has been appointed to the board of Agilent Technologies, broadening his leadership influence in the healthcare sector. Lastly, ...